Skip to main content
Clinical Trials/NCT05673096
NCT05673096
Recruiting
N/A

Paediatric Autism Communication Therapy (PACT) Combined With Management as Usual Compared to Management as Usual Alone in Children With Autism Spectrum Disorder - a Pragmatic, National, Randomised Clinical Trial

University of Southern Denmark6 sites in 1 country280 target enrollmentMarch 13, 2023

Overview

Phase
N/A
Intervention
Not specified
Conditions
Autism Spectrum Disorder
Sponsor
University of Southern Denmark
Enrollment
280
Locations
6
Primary Endpoint
Autism Symptoms
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

Paediatric Autism Communication Therapy (PACT) is a naturalistic developmental behavioural interventions to reduce autism symptoms. The aim of this trial is to assess the beneficial and harmful effects of PACT in 2-6 year-old children with a recent diagnosis of autism spectrum disorder.

Detailed Description

Autism spectrum disorder (ASD) is a neurodevelopmental disorder affecting approximately 2% of children and young people worldwide. ASD is considered a lifelong disorder and interventions significantly reducing the core autistic symptoms have been sparse. Paediatric Autism Communication Therapy (PACT) is among the first naturalistic developmental behavioural interventions to show promising results for reduction in autism symptoms. The aim of this trial is to assess the beneficial and harmful effects of PACT in 2-6 year-old children with a recent diagnosis of ASD. This trial is an investigator-initiated, independently funded, pragmatic, national, parallel group, superiority, randomised clinical trial comparing PACT combined with management as usual to management as usual alone.

Registry
clinicaltrials.gov
Start Date
March 13, 2023
End Date
December 31, 2026
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Children aged 2 through 6 years (both inclusive)
  • A diagnosis of ASD meeting the criteria for International Classification of Diseases; Tenth Edition (ICD-10): Diagnose codes: DF84.0, DF84.1, DF84.5, DF84.8
  • An Autism Diagnostic Observation Schedule, 2nd Edition Calibrated Severity Score (ADOS-2 CSS) ≥ 4
  • The ASD diagnosis must be verified by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), Autism Spectrum Disorder Checklist
  • The ASD diagnosis must be the primary developmental disorder (comorbid conditions allowed) and conferred at a clinical conference
  • Parents must have sufficient Danish (or English) language skills to communicate with the therapist
  • Signed informed consent by parents or holders of legal guardianship

Exclusion Criteria

  • Children having a sibling already included in the trial
  • Hearing and visual impairment in child or parent
  • Parent not available for regular sessions with the therapist, evaluated at the consent meeting

Outcomes

Primary Outcomes

Autism Symptoms

Time Frame: End of intervention (14 months)

Autism symptoms are measured by Diagnostic Observation schedule, 2nd Edition, Calibrated Severity Score (ADOS-2 CSS). Range 0-10, with 10 indicating the highest symptom severity.

Secondary Outcomes

  • Quality of Life (child)(End of intervention (14 months))
  • Quality of life (parents)(End of intervention (14 months))
  • Child adaptive functioning(End of intervention (14 months))
  • Social interaction of the child(At 6 month and end of intervention (14 months))

Study Sites (6)

Loading locations...

Similar Trials